Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Endonovo Therapeutics Inc (ENDV)

Endonovo Therapeutics Inc (ENDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 866
  • Shares Outstanding, K 333,038
  • Annual Sales, $ 140 K
  • Annual Income, $ -18,470 K
  • 60-Month Beta -1.41
  • Price/Sales 3.21
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ENDV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings $0.00 on 12/28/23
  • Latest Earnings Date 05/27/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0020 +25.00%
on 03/27/24
0.0058 -56.90%
on 03/28/24
-0.0009 (-26.47%)
since 03/22/24
3-Month
0.0010 +150.00%
on 02/07/24
0.0093 -73.12%
on 01/23/24
-0.0068 (-73.12%)
since 01/22/24
52-Week
0.0010 +150.00%
on 02/07/24
0.0200 -87.50%
on 05/05/23
-0.0135 (-84.38%)
since 04/21/23

Most Recent Stories

More News
Endonovo Therapeutics Releases Comparative Analysis Demonstrating

More Effective SofPulse® Results Compared With Bioelectronics RecoveryRx® Los Angeles, CA, July 28, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics...

ENDV : 0.0025 (-3.85%)
Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management

Los Angeles, CA, July 21, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today released a comparative analysis detailing how its...

ENDV : 0.0025 (-3.85%)
Endonovo Therapeutics Announces LOI to Acquire Specialty Construction Company

Los Angeles, CA, June 09, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today announced a Letter of Intent to purchase a...

OTC.VN : 0.325 (-4.41%)
ENDV : 0.0025 (-3.85%)
$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement

Los Angeles, CA, April 11, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced significant advancement in the of process...

OTC.VN : 0.325 (-4.41%)
ENDV : 0.0025 (-3.85%)
Stanford University Orthopedic Study Collaboration with Endonovo Therapeutics SofPulse® Devices Moves Forward

Los Angeles, CA, May 11, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced completion of Shipment of SofPulse ® tPEMF Devices for use...

ENDV : 0.0025 (-3.85%)
Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic.

LOS ANGELES, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today a new marketing and public awareness campaign around their FDA...

ENDV : 0.0025 (-3.85%)
Endonovo Therapeutics Announces Encore Live Webinar of Baylor College of Medicine Study For Patients Undergoing Cardiothoracic Surgery Showing Reduction of Pain and Opioid Use With Significant Reduction of Length of Stay Using SofPulse®

LOS ANGELES, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced an additional opportunity to view a live webinar presentation...

ENDV : 0.0025 (-3.85%)
Endonovo Therapeutics, Inc. Announces Second Quarter Fiscal 2020 Financial Results

LOS ANGELES, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced financial and operating results for the second quarter ended June...

ENDV : 0.0025 (-3.85%)
Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®

LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that an investigator initiated study, authored by Dr. Samir Awad,...

ENDV : 0.0025 (-3.85%)
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing

Los Angeles, CA, July 21, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced the Company’s registration statement on Form S-1 relating...

ENDV : 0.0025 (-3.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Endonovo Therapeutics, Inc. is a biotechnology company which is engaged in developing a bioelectronic approach to regenerative medicine. The company's Immunotronics(TM) platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction...

See More

Key Turning Points

3rd Resistance Point 0.0027
2nd Resistance Point 0.0026
1st Resistance Point 0.0026
Last Price 0.0025
1st Support Level 0.0025
2nd Support Level 0.0024
3rd Support Level 0.0024

See More

52-Week High 0.0200
Fibonacci 61.8% 0.0127
Fibonacci 50% 0.0105
Fibonacci 38.2% 0.0083
Last Price 0.0025
52-Week Low 0.0010

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar